Drug Trial Radar · NCT06376136
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
May 8, 2024
Primary completion
Feb 29, 2028
Study completion May 30, 2028
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Apr 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open, exploratory Phase Ib/IIa clinical trial in humans The combination of BAT8010 and BAT1006 was administered in patients with locally advanced or metastatic solid tumors(HER-2 expression, including IHC3+, IHC2+/FISH+, and IHC2+/FISH- patients)Tolerance and PK characteristics, to explore the maximum tolerated dose (MTD) and provide recommendations for subsequent clinical studies Recommended dose (RP2D) and rational administration regimen, and preliminary evaluation of antitumor efficacy. There are two main studies In the first stage, the "3+3" dose escalation rule is proposed to explore the safety and tolerance of the drug Sex; The second stage selects the appropriate dose and administration according to the preliminary safety and efficacy results of the previous stage The drug regimen and tumor species were expanded to further explore the combination of BAT8010 and BAT1006 for injection,The safety and clinical effectiveness of drug administration provided the basis for the follow-up clinical study.
Conditions
- Advanced Solid Tumors
Interventions
BAT8010 for InjectionDrug
Intravenous
BAT1006 for InjectionDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: The first administration cycle(21 days)
- vital signsTime frame: Through study completion, 1 year
- Physical examinationTime frame: Through study completion, 1 year
- Adverse eventsTime frame: From the first receipt of the investigational drug until 28 (+7) days after the last receipt of the investigational drug or the initiation of a new antitumor therapy, whichever occurs earlier,assessed up to 1 year
- Clinical laboratory testsTime frame: Through study completion, 1 year
- Number of participants with abnormal clinical auxiliary testsTime frame: Through study completion, 1 year
- Duration of Response(DOR)Time frame: Through study completion, 1 year
- Disease Control Rate (DCR)Time frame: Through study completion, 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.